Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetaphil Daily Facial Moisturizer with SPF 50+ is an over-the-counter (OTC) sunscreen and moisturizer developed by Galderma. It is formulated with a combination of chemical filters (octinoxate, octisalate, octocrylene, and oxybenzone) and a physical blocker (titanium dioxide) to provide broad-spectrum protection against UV radiation. The product is specifically designed for sensitive, dry to normal skin types and is indicated for the prevention of sunburn. It has undergone Phase 4 Human Repeat Insult Patch Test (HRIPT) studies to confirm its safety profile regarding skin irritation and sensitization potential in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetaphil Daily Facial Moisturizer with SPF 50+.